ENGN

enGene Holdings Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website engene.com
Employees(FY) 31
ISIN CA29286M1059

Performance

-11.97%

-16.85%

+41.24%

-42.22%

-18.74%

YTD

-11.35%

Profile

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Advanced Technical Analysis

Technical Analysis of ENGN 2024-11-20

The stock's Moving Average Score of 10 indicates a strong bearish sentiment, while the Oscillators Score of 46 suggests a neutral stance. Overall, the combined Technical Score of 28 reinforces a bearish outlook, signaling potential challenges for upward price movement in the near term.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ENGN

Stock Rank

Recent News & Updates

2024-11-04 19:00
enGene to Participate in Guggenheims Inaugural Healthcare Innovation Conference(Businesswire)
2024-10-24 20:00
enGene Announces $60 Million Private Placement Financing(Businesswire)
2024-10-22 04:05
enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)(Businesswire)
2024-10-20 20:45
enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer(Businesswire)
2024-10-01 04:05
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)(Businesswire)
2024-09-25 18:30
Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort(Businesswire)
2024-09-14 10:08
enGene Holdings Inc. (ENGN): Wall Street Analysts Recommend This Canadian Stocks Right Now(Insidermonkey)
2024-09-10 04:33
enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update(Businesswire)
2024-08-28 04:05
enGene to Participate in Upcoming Investor Conferences(Businesswire)
2024-07-24 04:05
enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)(Businesswire)
2024-07-23 18:30
enGene Announces Appointment of Ron Cooper as Chief Executive Officer(Businesswire)
2024-07-17 20:00
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors(Globenewswire)
2024-06-14 07:01
enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update(Business Wire)
2024-06-13 19:01
enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update(Businesswire)
2024-05-29 07:30
enGene to Present at the Jefferies Global Healthcare Conference(Business Wire)
2024-05-28 19:30
enGene to Present at the Jefferies Global Healthcare Conference(Businesswire)
2024-05-15 16:05
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors(Business Wire)
2024-05-15 04:05
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors(Businesswire)
2024-05-02 16:05
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting(CNW Group)
2024-05-02 04:05
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting(Prnewswire)
2024-04-23 06:56
Daily â€“ Vickers Top Buyers & Sellers for 04/23/2024(Argus Research)
2024-04-09 08:00
enGene Announces Hiring of Dr. Raj Pruthi as Senior Vice President, Urologic Oncology and Clinical Development(CNW Group)
2024-04-08 20:56
/C O R R E C T I O N -- enGene Inc./(Prnewswire)
2024-04-08 20:00
engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development(Prnewswire)
2024-03-11 16:05
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress(PR Newswire)
2024-03-11 05:16
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress(Prnewswire)
2024-03-05 07:00
enGene To Present at the Leerink Partners Global Biopharma Conference(CNW Group)
2024-03-04 18:00
enGene To Present at the Leerink Partners Global Biopharma Conference(Prnewswire)
2024-02-14 06:50
enGene Announces Oversubscribed $200 Million Private Placement Financing(PR Newswire)
2024-02-14 06:45
enGene Announces Leadership Succession Plan(PR Newswire)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.